Shenzhen:688321.SZ News & Press Release Distribution

Shenzhen:688321.SZ

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

SHENZHEN, China, March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for non-alcoholic steatoh...

2024-03-18 19:25 1732

Week's Top Stories

Most Reposted

Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution

[Picked up by 313 media titles]

2024-11-21 10:30

Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation

[Picked up by 308 media titles]

2024-11-20 13:29

Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions

[Picked up by 301 media titles]

2024-11-20 16:30

Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions

Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025

[Picked up by 298 media titles]

2024-11-19 10:42

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 284 media titles]

2024-11-20 09:00